Insider Selling: Pharvaris (NASDAQ:PHVS) CEO Sells $65,551.20 in Stock

Pharvaris N.V. (NASDAQ:PHVS) CEO Berndt Modig sold 2,292 shares of the stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $28.60, for a total transaction of $65,551.20. Following the transaction, the chief executive officer directly owned 139,792 shares in the company, valued at approximately $3,998,051.20. This represents a 1.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Berndt Modig also recently made the following trade(s):

• On Thursday, April 9th, Berndt Modig sold 23,333 shares of Pharvaris stock. The shares were sold at an average price of $27.74, for a total transaction of $647,257.42.

Pharvaris Trading Up 3.1%

Shares of PHVS stock opened at $30.04 on Thursday. The company has a market cap of $1.96 billion, a PE ratio of -8.91 and a beta of -2.58. The company’s fifty day simple moving average is $27.37 and its 200-day simple moving average is $25.79. Pharvaris N.V. has a 52 week low of $14.59 and a 52 week high of $30.24.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.15). Equities research analysts expect that Pharvaris N.V. will post -3.19 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Pharvaris in a report on Tuesday, March 3rd. Wedbush raised their target price on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Thursday, January 22nd. Wolfe Research assumed coverage on Pharvaris in a report on Thursday, April 9th. They set an “outperform” rating and a $42.00 target price on the stock. Finally, Wall Street Zen downgraded Pharvaris from a “sell” rating to a “strong sell” rating in a report on Monday, April 13th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Pharvaris currently has a consensus rating of “Moderate Buy” and an average price target of $42.73.

Institutional Investors Weigh In On Pharvaris

Large investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new stake in Pharvaris during the 4th quarter valued at $35,000. Barclays PLC acquired a new stake in Pharvaris during the 4th quarter valued at $77,000. China Universal Asset Management Co. Ltd. acquired a new stake in Pharvaris during the 3rd quarter valued at $75,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Pharvaris during the 4th quarter valued at $86,000. Finally, JPMorgan Chase & Co. grew its holdings in Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares in the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.